PDF(1286 KB)
PDF(1286 KB)
PDF(1286 KB)
小檗碱聚乳酸微球的制备工艺及特性研究
Preparation and characteristics of berberine polylactic acid microspheres
采用溶剂挥发法制备小檗碱聚乳酸微球, 选择小檗碱与聚乳酸的投料比、二氯甲烷与水的体积比和乳化剂PVA的质量分数3个因素为实验因素，以包封率和载药量为优化指标, 采用L9(34)正交试验优选最佳处方和制备工艺,测定微球的粒径分布、包封率,并进行体外释药试验。小檗碱聚乳酸微球的算术平均粒径为(53.0±3.5)μm(n=500),载药量为(8.96±0.3)%(n=3),药物包封率为(83.4±0.5)%(n=3)，37℃时30d内微球体外累积释药量为82.03%。小檗碱聚乳酸微球球形圆整,释放良好，分子量2.5万左右的聚乳酸较适宜制作微球。
Microspheres containing berberine and polylactic acid were prepared by an oil-in-water emulsifying solvent-evaporation process. The proportions of berberine and polylactic acid, dichloromethane and water, and concentration of PVA were taken as the three experimental factors in an L9(34) orthogonal design in order to find the optimum conditions. The distribution of particle sizes, the encapsulation ratio and in vitro release rate were measured. The mean particle diameter was found to be (53.0±3.5) μm(n=500), the drug loading was (8.96±0.3)% (n=3), and the encapsulation efficiency was (83.4±0.5)% (n=3). The in vitro accumulated release rate of the microspheres was found to be 82.03% after 30 days at 37℃. These data indicate that PLA having molecular weight of 25000 is a suitable material for preparing berberine microspheres for controlled release.
［1］ 徐丽君，陆付耳，魏世超, 等. 盐酸小檗碱脂质体的制备方法及质量研究［J］. 中国医院药学杂志，2004，24(6)：325-326.
［2］ Chognot D, Léonard M, Six J L, et al. Surface water-soluble copolymers for the preparation of controlled surface nanoparticles by double emulsion/solvent evaporationd［J］. Colloids and Surfaces B: Biointerfaces, 2006, 51(1): 86-92.
［3］ 吴珍珍，李馨儒, 胡应生, 等. 辛伐他汀聚乳酸微球的制备及药剂学性质［J］. 中国新药杂志，2005，14(11):1312-1315.
［4］ 李良，李国明. W/O法制备盐酸土霉素/聚乳酸微球及其释药性能［J］. 中国现代应用药学杂志，2005，22(1):49-52.
［5］ 李德冠，姜丹，姜云垒, 等. 聚乳酸微球的制备［J］. 吉林大学学报：理学版，2005，43(6):842-847.
［6］ Slager J, Domb A J. Hetero-stereocomplexes of D-poly(lactic acid) and the LHRH analogue leuprolide. Application in controlled release［J］. European Journal of Pharmaceutics and Biopharmaceutics, 2004, 58: 461-469.
［7］ Liang H F, Yang T F, Huang C T, et al. Preparation of nanoparticles composed of poly(γ-glutamic acid)-poly(lactide) block copolymers and evaluation of their uptake by HepG2 cells［J］. Journal of Controlled Release, 2005,105(3)：213-225.
［8］ Biggs D L, Lengsfeld C S, Hybertson B M, et al. In vitro and in vivo evaluation of the effects of PLA microparticle crystallinity on cellular response［J］. Journal of Controlled Release, 2003, 92(1-2):147-161.
［9］ 费正奇，胡蕴玉，张德志, 等. 携载rhBMP2微球的新型复合人工骨的释药及成骨活性研究［J］. 中华实验外科杂志，2006，23(2):151-156.
［10］ Kranz H, Bodmeier R. A novel in situ forming drug delivery system for controlled parenteral drug delivery［J］. International Journal of Pharmaceutics, 2007, 332(1-2): 107-114.
/
| 〈 |
|
〉 |
